AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24417762 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable partial dentures (RPDs)
Number of subjects: 116
Study 24417762 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 116
Study 24417762 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐36 test
Number of subjects: 116
Study 23342571 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (50% N2O/50% O2)
Number of subjects: 0
Study 23342571 — intervention group
Group type: COMPARATOR
Intervention: Protocol B (100% O2)
Number of subjects: 0
Study 20726885 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 0
Study 20726885 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 0
Study 20726885 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 20726885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study 20726885 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 0
Study 20726885 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 20726885 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 20726885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18258986 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative AC (doxorubicin and cyclophosphamide)
Number of subjects: 3037
Study 18258986 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative AC followed by surgery and T
Number of subjects: 3037
Study 18258986 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients achieving pCR
Number of subjects: 3037
Study 16344402 — intervention group
Group type: EXPERIMENTAL
Intervention: NCEP-defined metabolic syndrome
Number of subjects: 822
Study 16344402 — intervention group
Group type: EXPERIMENTAL
Intervention: International Diabetes Federation metabolic syndrome
Number of subjects: 822
Study 16344402 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified NCEP metabolic syndrome definitions
Number of subjects: 822
Study 16344402 — intervention group
Group type: EXPERIMENTAL
Intervention: IR and inflammation variables
Number of subjects: 822
Study 12807998 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (Cmax >50 microg/ml)
Number of subjects: 51
Study 12807998 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (Cmax <50 microg/ml)
Number of subjects: 51
Study 11212064 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 37
Study 11212064 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 37
Study 11212064 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide-amiloride
Number of subjects: 37
Study 11212064 — intervention group
Group type: COMPARATOR
Intervention: Atenolol and hydralazine (as secondary and tertiary drugs)
Number of subjects: 37
Study 8857564 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus high zone (0.6-1.2 ng/ml) in Primary Biliary Cirrhosis study group
Number of subjects: 0
Study 8857564 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus low zone (0.1-0.6 ng/ml) in Primary Biliary Cirrhosis study group
Number of subjects: 0
Study 8857564 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus concentration range (0.3-0.7 ng/ml) in Multiple Sclerosis study group
Number of subjects: 0
Study 1642347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (0.027 mg) with 6 ml sodium chloride 0.9% intravenously
Number of subjects: 42
Study 1642347 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (0.027 mg) with six sprays of sodium chloride 0.9% intranasally
Number of subjects: 42
Study 6424496 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical defined diet (CDD) via intrajejunal tube
Number of subjects: 40
Study 6424496 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition via central veins (Control)
Number of subjects: 40
Study 31445454 — intervention group
Group type: EXPERIMENTAL
Intervention: SB3 (trastuzumab biosimilar)
Number of subjects: 367
Study 31445454 — intervention group
Group type: COMPARATOR
Intervention: TRZ (reference trastuzumab)
Number of subjects: 367
Study 31445454 — intervention group
Group type: EXPERIMENTAL
Intervention: SB3
Number of subjects: 367
Study 31445454 — intervention group
Group type: COMPARATOR
Intervention: TRZ
Number of subjects: 367
Study 31445454 — intervention group
Group type: EXPERIMENTAL
Intervention: SB3 and TRZ
Number of subjects: 367
Study 29247141 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate (SVA)
Number of subjects: 11949
Study 29247141 — intervention group
Group type: COMPARATOR
Intervention: Other antiepileptic drugs
Number of subjects: 11949
Study 27177240 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low HDL-C (<30 mg/dL)
Number of subjects: 9064
Study 27177240 — intervention group
Group type: COMPARATOR
Intervention: Higher HDL-C (≥30 mg/dL)
Number of subjects: 9064
Study 24479409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of rAd-p53 plus chemotherapy (group I, n = 35)
Number of subjects: 99
Study 24479409 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial infusion of rAd-p53 plus placebo chemotherapy (group II, n = 33)
Number of subjects: 99
Study 24479409 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial infusion of placebo rAd-p53 plus chemotherapy (group III, n = 31)
Number of subjects: 99
Study 24479409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of rAd-p53 plus chemotherapy (group I)
Number of subjects: 99
Study 21208247 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/paracetamol (5/325 mg), four times daily for 3 days
Number of subjects: 246
Study 21208247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 21208247 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/paracetamol (5/325 mg)
Number of subjects: 246
Study 20646695 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 oz oral sulfate solution (OSS) given in equally divided doses the evening before and the morning of colonoscopy
Number of subjects: 136
Study 20646695 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 oz oral sulfate solution (OSS)
Number of subjects: 136
Study 20646695 — intervention group
Group type: COMPARATOR
Intervention: 4 L sulfate-free electrolyte lavage solution (SF-ELS)
Number of subjects: 136
Study 17443195 — intervention group
Group type: EXPERIMENTAL
Intervention: High human milk (HHM) feeding (≥50% HM)
Number of subjects: 202
Study 17443195 — intervention group
Group type: COMPARATOR
Intervention: Low human milk (LHM) feeding (<50% HM)
Number of subjects: 202
Study 16036344 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamin C 100 mg, vitamin E 100 mg, β-carotene 6 mg, selenium 50 µg) for 12 weeks
Number of subjects: 124
Study 16036344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 16036344 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 124
Study 12422299 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 0
Study 12422299 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 9541437 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (50 mg per day)
Number of subjects: 1072
Study 9541437 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg per day)
Number of subjects: 1072
Study 9541437 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol and beta-carotene (both)
Number of subjects: 1072
Study 9541437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1072
Study 7973898 — intervention group
Group type: COMPARATOR
Intervention: Usual intubation method (bevel to the left, tube concave anteriorly)
Number of subjects: 60
Study 7973898 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 degrees counterclockwise rotation of the tracheal tube during insertion
Number of subjects: 60
Study 7973898 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevel altered to face the right, tube concave anteriorly
Number of subjects: 60
Study 2789953 — intervention group
Group type: EXPERIMENTAL
Intervention: Public education campaign for melanoma diagnosis
Number of subjects: 0
Study 4823547 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg hydroxyzine
Number of subjects: 58
Study 4823547 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg hydroxyzine
Number of subjects: 58
Study 4823547 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg hydroxyzine
Number of subjects: 58
Study 4823547 — intervention group
Group type: COMPARATOR
Intervention: 60 mg pentobarbital
Number of subjects: 58
Study 4823547 — intervention group
Group type: COMPARATOR
Intervention: 180 mg pentobarbital
Number of subjects: 58
Study 30252544 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitator-led approach to implementing SDM
Number of subjects: 6544
Study 30252544 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch-and-learn training on SDM
Number of subjects: 6544
Study 30252544 — intervention group
Group type: COMPARATOR
Intervention: Control group with no active intervention
Number of subjects: 6544
Study 28809926 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified SQ-LNS for 12 weeks (MMN-12)
Number of subjects: 1101
Study 28809926 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified SQ-LNS for 6 weeks followed by unfortified SQ-LNS for 6 weeks (MMN-6)
Number of subjects: 1101
Study 28809926 — intervention group
Group type: COMPARATOR
Intervention: Unfortified SQ-LNS for 12 weeks (MMN-0)
Number of subjects: 1101
Study 28809926 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified SQ-LNS (combined MMN-12 and MMN-6)
Number of subjects: 1101
Study 28809926 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (MMN-0, MMN-6, MMN-12)
Number of subjects: 1101
Study 26553084 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) guided antibiotic treatment
Number of subjects: 60
Study 26553084 — intervention group
Group type: COMPARATOR
Intervention: Empiric antibiotic therapy (Control)
Number of subjects: 60
Study 24131298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed QM training program (IG)
Number of subjects: 38
Study 24131298 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (CG)
Number of subjects: 38
Study 24131298 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IG and CG)
Number of subjects: 38
Study 22117987 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (0.5 mg/kg loading dose followed by infusion of 30 μg/kg per min)
Number of subjects: 54
Study 22117987 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 54
Study 22117987 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 54
Study 19857748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of CD133+ stem cells
Number of subjects: 14
Study 19857748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 16835340 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg p.o. bid)
Number of subjects: 25
Study 16835340 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg p.o. bid)
Number of subjects: 25
Study 16835340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 12765916 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 microg twice daily
Number of subjects: 528
Study 12765916 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 100 microg twice daily
Number of subjects: 528
Study 10743991 — intervention group
Group type: EXPERIMENTAL
Intervention: WOMAC osteoarthritis index
Number of subjects: 58
Study 10743991 — intervention group
Group type: COMPARATOR
Intervention: NHP
Number of subjects: 58
Study 10743991 — intervention group
Group type: COMPARATOR
Intervention: SF-36
Number of subjects: 58
Study 8858786 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical models for treatment comparison
Number of subjects: 0
Study 8858786 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum likelihood (ML) and restricted maximum likelihood (REML) approaches
Number of subjects: 0
Study 8858786 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-form expressions for variance component estimators
Number of subjects: 0
Study 1563665 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (group A)
Number of subjects: 20
Study 1563665 — intervention group
Group type: COMPARATOR
Intervention: Sham training (group B)
Number of subjects: 20
Study 3907396 — intervention group
Group type: EXPERIMENTAL
Intervention: etomidate + fentanyl
Number of subjects: 20
Study 3907396 — intervention group
Group type: EXPERIMENTAL
Intervention: flunitrazepam + fentanyl
Number of subjects: 20
Study 3433091 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acetylsalicylic acid (ASA) and dihydroergotamine (DHE)
Number of subjects: 202
Study 3433091 — intervention group
Group type: COMPARATOR
Intervention: Acenocoumarol
Number of subjects: 202
Study 31469677 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai-Chi
Number of subjects: 63
Study 31469677 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 63
Study 29305739 — intervention group
Group type: COMPARATOR
Intervention: LL group (TI-scout followed T1-mapping)
Number of subjects: 130
Study 29305739 — intervention group
Group type: COMPARATOR
Intervention: MOLLI group (T1-mapping followed TI-scout)
Number of subjects: 130
Study 28251569 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined balance and core resistance training (n=14)
Number of subjects: 28
Study 28251569 — intervention group
Group type: COMPARATOR
Intervention: Pilates training (n=14)
Number of subjects: 28
Study 26195247 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated original multicomponent intervention programme
Number of subjects: 10800
Study 26195247 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise version of the updated programme
Number of subjects: 10800
Study 26195247 — intervention group
Group type: COMPARATOR
Intervention: Optimised usual care (Control group)
Number of subjects: 10800
Study 22198323 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous tantalum ring device packed with autograft
Number of subjects: 39
Study 22198323 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous tantalum block device
Number of subjects: 39
Study 22198323 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest autograft control
Number of subjects: 39
Study 21383072 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem conditioning
Number of subjects: 0
Study 21383072 — intervention group
Group type: EXPERIMENTAL
Intervention: Outgroup stereotype priming
Number of subjects: 0
Study 18326594 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary betaine (approximately 517 mg)
Number of subjects: 8
Study 18326594 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary betaine (approximately 500 mg)
Number of subjects: 8
Study 18326594 — intervention group
Group type: EXPERIMENTAL
Intervention: High-betain meal (approximately 517 mg)
Number of subjects: 8
Study 18326594 — intervention group
Group type: EXPERIMENTAL
Intervention: High-betain and high-choline meal (approximately 517 mg betaine, approximately 622 mg choline)
Number of subjects: 8
Study 18326594 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary betaine and choline
Number of subjects: 8
Study 18326594 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine supplementation
Number of subjects: 8
Study 18326594 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline supplement (500 mg)
Number of subjects: 8
Study 18326594 — intervention group
Group type: COMPARATOR
Intervention: Low-betain and -choline control meal
Number of subjects: 8
Study 16598426 — intervention group
Group type: EXPERIMENTAL
Intervention: Estramustine + radiotherapy
Number of subjects: 122
Study 16598426 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only
Number of subjects: 122
Study 14555895 — intervention group
Group type: EXPERIMENTAL
Intervention: No Rub Opti-Free Express MPS (Alcon)
Number of subjects: 89
Study 14555895 — intervention group
Group type: COMPARATOR
Intervention: Complete MPS (Allergan)
Number of subjects: 89
Study 14555895 — intervention group
Group type: EXPERIMENTAL
Intervention: ReNu MultiPlus MPS (Bausch & Lomb)
Number of subjects: 89
Study 14555895 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 1 (No Rub Opti-Free Express MPS)
Number of subjects: 89
Study 14555895 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 3 (ReNu MultiPlus MPS)
Number of subjects: 89
Study 10979637 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpirid monotherapy (200-450 mg/day)
Number of subjects: 40
Study 10979637 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy (combined treatment with spasmolytic, bacterial and cholagogic drugs)
Number of subjects: 40
Study 8629624 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-protein diet (0.28 g/kg/d) supplemented with keto acids-amino acids (0.28 g/kg/d)
Number of subjects: 255
Study 8629624 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (0.58 g/kg/d)
Number of subjects: 255
Study 8629624 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets combined (controlled for baseline factors)
Number of subjects: 255
Study 8629624 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-protein diet
Number of subjects: 255
Study 8629624 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets combined
Number of subjects: 255
Study 1465791 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil administration in cyclosporine-treated patients
Number of subjects: 20
Study 1465791 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine treatment
Number of subjects: 20
Study 1465791 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine treatment
Number of subjects: 20
Study 6587408 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms thromboxane B2 (TXB2)
Number of subjects: 30
Study 6587408 — intervention group
Group type: COMPARATOR
Intervention: Diluted ethanol (control)
Number of subjects: 30
Study 31920054 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste (PT) and placebo bleaching (PB)
Number of subjects: 15
Study 31920054 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothpaste (CT) and PB
Number of subjects: 15
Study 31920054 — intervention group
Group type: COMPARATOR
Intervention: Whitening toothpaste (WT) and PB
Number of subjects: 15
Study 31920054 — intervention group
Group type: EXPERIMENTAL
Intervention: PT and H2O2
Number of subjects: 15
Study 31920054 — intervention group
Group type: EXPERIMENTAL
Intervention: CT and H2O2
Number of subjects: 15
Study 31920054 — intervention group
Group type: EXPERIMENTAL
Intervention: WT and H2O2
Number of subjects: 15
Study 28872444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice only
Number of subjects: 15
Study 28872444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice and compression
Number of subjects: 15
Study 28872444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice and elevation
Number of subjects: 15
Study 28872444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice, compression, and elevation
Number of subjects: 15
Study 28872444 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 15
Study 28872444 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression only
Number of subjects: 15
Study 28872444 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevation only
Number of subjects: 15
Study 28872444 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression and elevation
Number of subjects: 15
Study 27195704 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation facilitated by lay navigators trained by professional social workers
Number of subjects: 47
Study 23920031 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive hydration with lactated Ringer's solution (3 mL/kg/h during the procedure, a 20-mL/kg bolus after the procedure, and 3 mL/kg/h for 8 hours after the procedure)
Number of subjects: 62
Study 23920031 — intervention group
Group type: COMPARATOR
Intervention: Standard hydration with lactated Ringer's solution (1.5 mL/kg/h during and for 8 hours after procedure)
Number of subjects: 62
Study 23920031 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive hydration with lactated Ringer's solution
Number of subjects: 62
Study 23920031 — intervention group
Group type: COMPARATOR
Intervention: Standard hydration with lactated Ringer's solution
Number of subjects: 62
Study 21846962 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pulmonary rehabilitation (within 2 weeks)
Number of subjects: 36
Study 21846962 — intervention group
Group type: COMPARATOR
Intervention: Late pulmonary rehabilitation (starting 6 months after randomization)
Number of subjects: 36
Study 21846962 — intervention group
Group type: COMPARATOR
Intervention: Late pulmonary rehabilitation
Number of subjects: 36
Study 21846962 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pulmonary rehabilitation
Number of subjects: 36
Study 20223555 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1.5% eye drops, twice daily for 3 days
Number of subjects: 1043
Study 20223555 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin 0.3%, 1 drop every 2 hours for 2 days, then four times daily for 5 days
Number of subjects: 1043
Study 18715414 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (25 micrograms initially, followed by 25 micrograms after 4 and 8 hours; 50 micrograms for nulliparous women with Bishop score ≤4)
Number of subjects: 626
Study 18715414 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone (3 mg initially, followed by 3 mg after 6 hours)
Number of subjects: 626
Study 18715414 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol and Dinoprostone (both groups)
Number of subjects: 626
Study 15983179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (400-800 IU daily)
Number of subjects: 573
Study 12072669 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD) with 400 mg of norfloxacin once daily preoperatively and postoperative treatment with 2 mg of colistin, 1.8 mg of tobramycin, and 10 mg of amphotericin B, four times daily, until postoperative day 30.
Number of subjects: 55